BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wagenlehner FM, van Till JO, Houbiers JG, Martina RV, Cerneus DP, Melis JH, Majek A, Vjaters E, Urban M, Ramonas H, Shoskes DA, Nickel JC. Fatty Acid Amide Hydrolase Inhibitor Treatment in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: An Adaptive Double-blind, Randomized Controlled Trial. Urology 2017;103:191-7. [DOI: 10.1016/j.urology.2017.02.029] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Franco JV, Turk T, Jung JH, Xiao YT, Iakhno S, Tirapegui FI, Garrote V, Vietto V. Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. Cochrane Database Syst Rev 2019;10:CD012552. [PMID: 31587256 DOI: 10.1002/14651858.CD012552.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
2 Takizawa M, Cerneus D, Michon I, Rijnders S, Meijer J, Someya A, Sato Y. Investigation of Safety and Tolerability of ASP3652 Based on Clinical Studies of Cerebrospinal Fluid Transfer After Multiple Doses and Exposure After Single Doses at High Dose Levels. Adv Ther 2020;37:3967-84. [PMID: 32715381 DOI: 10.1007/s12325-020-01451-6] [Reference Citation Analysis]
3 Fowler CJ. The endocannabinoid system - current implications for drug development. J Intern Med 2021;290:2-26. [PMID: 33348434 DOI: 10.1111/joim.13229] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Takizawa M, Cerneus D, Michon I, Rijnders S, van der Heide D, Meijer J, Stoelzel M, Sato Y. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652 in First-in-Human and Ascending Multiple Oral Dose Studies in Healthy Subjects. Adv Ther 2020;37:3878-900. [PMID: 32681461 DOI: 10.1007/s12325-020-01402-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Zaidi N, Thomas D, Chughtai B. Management of Chronic Prostatitis (CP). Curr Urol Rep 2018;19. [DOI: 10.1007/s11934-018-0841-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
6 Takizawa M, Hatta T, Iitsuka H, Katashima M, Sato Y, Kuroishi K, Nagashima H. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study. Clin Ther 2020;42:906-23. [PMID: 32456804 DOI: 10.1016/j.clinthera.2020.03.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Fitzcharles MA, Petzke F, Tölle TR, Häuser W. Cannabis-Based Medicines and Medical Cannabis in the Treatment of Nociplastic Pain. Drugs 2021;81:2103-16. [PMID: 34800285 DOI: 10.1007/s40265-021-01602-1] [Reference Citation Analysis]
8 Galaj E, Xi ZX. Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders. CNS Drugs 2019;33:1001-30. [PMID: 31549358 DOI: 10.1007/s40263-019-00664-w] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
9 Slivicki RA, Xu Z, Mali SS, Hohmann AG. Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro. Pharmacol Res 2019;142:267-82. [PMID: 30739035 DOI: 10.1016/j.phrs.2019.02.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
10 Finn DP, Haroutounian S, Hohmann AG, Krane E, Soliman N, Rice ASC. Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies. Pain 2021;162:S5-S25. [PMID: 33729211 DOI: 10.1097/j.pain.0000000000002268] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
11 Lafreniere JD, Kelly MEM. Potential for endocannabinoid system modulation in ocular pain and inflammation: filling the gaps in current pharmacological options. Neuronal Signal 2018;2:NS20170144. [PMID: 32714590 DOI: 10.1042/NS20170144] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
12 Taylor C, Birch B. Cannabinoids in Urology. Which Benign Conditions Might They Be Appropriate to Treat: A Systematic Review. Urology 2021;148:8-25. [PMID: 33129871 DOI: 10.1016/j.urology.2020.10.024] [Reference Citation Analysis]
13 Deplano A, Karlsson J, Moraca F, Svensson M, Cristiano C, Morgillo CM, Fowler CJ, Russo R, Catalanotti B, Onnis V. Design, synthesis and in vitro and in vivo biological evaluation of flurbiprofen amides as new fatty acid amide hydrolase/cyclooxygenase-2 dual inhibitory potential analgesic agents. J Enzyme Inhib Med Chem 2021;36:940-53. [PMID: 33896320 DOI: 10.1080/14756366.2021.1875459] [Reference Citation Analysis]
14 Franco JV, Turk T, Jung JH, Xiao YT, Iakhno S, Garrote V, Vietto V. Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. Cochrane Database Syst Rev 2018;5:CD012551. [PMID: 29757454 DOI: 10.1002/14651858.CD012551.pub3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
15 Kodani SD, Wan D, Wagner KM, Hwang SH, Morisseau C, Hammock BD. Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors. ACS Omega 2018;3:14076-86. [PMID: 30411058 DOI: 10.1021/acsomega.8b01625] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
16 Franco JV, Turk T, Jung JH, Xiao YT, Iakhno S, Garrote V, Vietto V. Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. Cochrane Database Syst Rev 2018;1:CD012551. [PMID: 29372565 DOI: 10.1002/14651858.CD012551.pub2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
17 Fowler CJ, Doherty P, Alexander SPH. Endocannabinoid Turnover. Adv Pharmacol 2017;80:31-66. [PMID: 28826539 DOI: 10.1016/bs.apha.2017.03.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
18 Pham MN, Hudnall MT, Nadler RB. Marijuana, Lower Urinary Tract Symptoms, and Pain in the Urologic Patient. Urology 2020;139:8-13. [PMID: 32027882 DOI: 10.1016/j.urology.2020.01.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
19 Sholler DJ, Huestis MA, Amendolara B, Vandrey R, Cooper ZD. Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids. Pharmacol Biochem Behav 2020;199:173059. [PMID: 33086126 DOI: 10.1016/j.pbb.2020.173059] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
20 Deplano A, Cipriano M, Moraca F, Novellino E, Catalanotti B, Fowler CJ, Onnis V. Benzylamides and piperazinoarylamides of ibuprofen as fatty acid amide hydrolase inhibitors. J Enzyme Inhib Med Chem 2019;34:562-76. [PMID: 30688118 DOI: 10.1080/14756366.2018.1532418] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
21 Capodice JL, Kaplan SA. The endocannabinoid system, cannabis, and cannabidiol: Implications in urology and men's health. Curr Urol 2021;15:95-100. [PMID: 34168527 DOI: 10.1097/CU9.0000000000000023] [Reference Citation Analysis]
22 Slivicki RA, Saberi SA, Iyer V, Vemuri VK, Makriyannis A, Hohmann AG. Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit. J Pharmacol Exp Ther 2018;367:551-63. [PMID: 30275151 DOI: 10.1124/jpet.118.252288] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
23 Stairs J, Maguire F, Lehmann C, Cox A. Cannabinoid Therapy in Female Pelvic Medicine and Reconstructive Surgery: Current Evidence and Future Directions. Curr Bladder Dysfunct Rep 2021;16:64-73. [DOI: 10.1007/s11884-021-00632-5] [Reference Citation Analysis]
24 Santoso AD, De Ridder D. Fatty Acid Amide Hydrolase: An Integrative Clinical Perspective. Cannabis Cannabinoid Res 2022. [PMID: 35900294 DOI: 10.1089/can.2021.0237] [Reference Citation Analysis]
25 Fisher E, Moore RA, Fogarty AE, Finn DP, Finnerup NB, Gilron I, Haroutounian S, Krane E, Rice ASC, Rowbotham M, Wallace M, Eccleston C. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain 2021;162:S45-66. [PMID: 32804836 DOI: 10.1097/j.pain.0000000000001929] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
26 Rankin L, Fowler CJ. The Basal Pharmacology of Palmitoylethanolamide. Int J Mol Sci 2020;21:E7942. [PMID: 33114698 DOI: 10.3390/ijms21217942] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
27 Morozov A, Bazarkin A, Babaevskaya D, Taratkin M, Kozlov V, Suvorov A, Spivak L, Mcfarland J, Russo GI, Enikeev D; EAU‐YAU Sexual and Reproductive Health Working Group. A systematic review and meta‐analysis of placebo effect in clinical trials on chronic prostatitis/chronic pelvic pain syndrome. The Prostate. [DOI: 10.1002/pros.24311] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Hossain MZ, Ando H, Unno S, Kitagawa J. Targeting Peripherally Restricted Cannabinoid Receptor 1, Cannabinoid Receptor 2, and Endocannabinoid-Degrading Enzymes for the Treatment of Neuropathic Pain Including Neuropathic Orofacial Pain. Int J Mol Sci 2020;21:E1423. [PMID: 32093166 DOI: 10.3390/ijms21041423] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]